Ro 7-0207 is a derivative of nitro-imidazole-ethanol, namely a-chloromethyl-2-methyl-5-nitro-1-imidazole -ethanol. The structural formula is shown in the Figure. Identical capsules were prepared, each containing 200 mg. of either Ro 7-0207 or metronidazole or a placebo. Treatment was allocated at random, and the code key was not opened until the trial was completed. All the patients were admitted to the ward for treatment and received one capsule three times a day for 10 days. Four remained in the ward during the 10-day period, and the other 45 were treated as inpatients for the first 5 days and then allowed to continue the treatment as outpatients, and to report back on the 10th day for further investigations. Darkground microscopical examinations of a saline suspension of secretion from the posterior vaginal fornix were made on the 5th and 10th days, and again 3 and 4 weeks after the start of treatment.
OH FIGURE Chemical structure of Ro 7-0207 is a light yellow, crystalline substance with a melting range of 74-79oC . The Identical capsules were prepared, each containing 200 mg. of either Ro 7-0207 or metronidazole or a placebo. Treatment was allocated at random, and the code key was not opened until the trial was completed. All the patients were admitted to the ward for treatment and received one capsule three times a day for 10 days. Four remained in the ward during the 10-day period, and the other 45 were treated as inpatients for the first 5 days and then allowed to continue the treatment as outpatients, and to report back on the 10th day for further investigations. Darkground microscopical examinations of a saline suspension of secretion from the posterior vaginal fornix were made on the 5th and 10th days, and again 3 and 4 weeks after the start of treatment.
Spontaneous complaints attributed to the test drugs were recorded and each patient was then questioned specifically about vaginal discharge, irritation of the vulva, dysuria, frequency of micturition, and malodour.
A complete neurological examination was carried out on admission, as well as haemoglobin, white blood cell count, serum bilirubin, alkaline phosphatase, albuminglobulin ratio, SGPT, blood urea, and microscopical examination and specific gravity of urine; these tests were done before starting treatment and again on the 5th and 10th days, and after 4 weeks.
Results
Twenty patients were treated with Ro 7-0207, twenty with metronidazole, and ten with placebo capsules. There were no defaulters in any of the groups. All who were given Ro 7-0207 were regarded as cured on the evidence of follow-up tests. Seventeen were negative for Trichomonas vaginalis on the 5th day of treatment and two by the 10th day, and all nineteen continued to have negative tests until the 4th week (Table I) . The one remaining patient had a positive test at the end of the 4th week, having been negative on three previous occasions (Table II) ; this was probably due to re-infection after the 3rd week, as she admitted sexual intercourse during this period. All but one patient in the Ro 7-0207 group stated that the discharge and irritation were much improved after starting the treatment; one continued to complain of discharge and irritation although objectively there was little discharge to see and the signs of vaginitis had decreased. In all these cases the signs improved rapidly and in most there was complete resolution of vaginitis within 1 or 2 weeks, when the original thin, frothy, yellow discharge became thicker and white and rapidly decreased in amount, usually within a few days. In nearly every case, the number of leucocytes seen in the smear showed a marked decrease and the number of epithelial cells increased. These changes often occurred within a few days of starting the treatment and in many cases no more than an occasional pus cell was seen at the end of the treatment. No adverse side-effects were found in any of the patients in the entire series. The adverse reactions looked for included dizziness, vertigo, incoordination of movement, disturbed gait or speech, Rombergism, and nystagmus. Blood pressure and pulse were checked regularly. None of the biochemical and haematological values deviated from normal.
Discussion
For well over 10 years metronidazole has been a main-stay in the management of vaginal trichomoniasis. It has been described as a therapeutic ideal for this condition because of its high cure rate, relative freedom from side-effects, and apparent ease of administration.
The cure rate has been as high as 98 per cent. (Keighley, 1971 ) in a prison community where the drug was administered under controlled conditions and re-infection was not possible. In other series initial failure rates of less than 10 per cent. have been reported (Rodin, King, Nicol, and Barrow, 1960; Watt and Jennison, 1962; Csonka, 1963; Wisdom and Dunlop, 1965) .
Newer compounds have since been made available for the treatment of vaginal trichomoniasis. Evans and Catterall (1971) 
